Pharmacological inhibition of p97 interferes with arsenic-induced degradation of PML. (A) U2OS PML^−/− + YFP-PML cells were either untreated (UT) or treated with 1 μM arsenic (As), 5 μM CB-5083, or a combination of arsenic and CB-5083 for the times indicated. Cell lysates were analyzed by Western blotting using an antibody to PML or Lamin A/C. (B) U2OS PML^−/− + YFP-PML cells were treated with 1 μM arsenic for the indicated times and 5 μM CB-5083 added at indicated times after the start of arsenic treatment. Cell lysates were analyzed by Western blotting using an antibody to PML or Lamin A/C. (C–E) U2OS PML^−/− + YFP-PML cells (C), U2OS cells (D), or U2OS + RNF4 cells (E) were either untreated (UT) or treated with 1 μM arsenic (As), 5 μM CB-5083, or a combination of arsenic and CB-5083 for the times indicated. Cell lysates were analyzed by Western blotting using an antibody to PML or Lamin A/C. Molecular weight markers are indicated in kD. Source data are available for this figure: SourceData F2.